Abdominal aortic aneurysm (AAA) is a silent, progressive disease with a high mortality and an increasing prevalence with aging. Smooth muscle cell (SMC) dysfunction contributes to gradual dilatation and eventual rupture of the aorta. Here we studied phenotypic characteristics in SMC cultured from end-stage human AAA (≥5 cm) and cells cultured from a porcine carotid artery (PCA) model of early and end-stage aneurysm. Human AAA-SMC presented a secretory phenotype and expressed elevated levels of the differentiation marker miR-145 (2.2-fold, p < 0.001) and the senescence marker SIRT-1 (1.3-fold, p < 0.05), features not recapitulated in aneurysmal PCA-SMC. Human and end-stage porcine aneurysmal cells were frequently multi-nucleated (3.9-fold, p < 0.001, and 1.8-fold, p < 0.01, respectively, vs. control cells) and displayed an aberrant nuclear morphology. Human AAA-SMC exhibited higher levels of the DNA damage marker γH2AX (3.9-fold, p < 0.01, vs. control SMC). These features did not correlate with patients' chronological age and are therefore potential markers for pathological premature vascular aging. Early-stage PCA-SMC (control and aneurysmal) were indistinguishable from one another across all parameters. The principal limitation of human studies is tissue availability only at the end stage of the disease. Refinement of a porcine bioreactor model would facilitate the study of temporal modulation of SMC behaviour during aneurysm development and potentially identify therapeutic targets to limit AAA progression.

Keywords:
Abdominal aortic aneurysm, human, Smooth muscle cells, Aging, DNA damage, Senescence
1.
Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, Evangelista A, Falk V, Frank H, Gaemperli O, Grabenwoger M, Haverich A, Iung B, Manolis AJ, Meijboom F, Nienaber CA, Roffi M, Rousseau H, Sechtem U, Sirnes PA, Allmen RS, Vrints CJ: 2014 ESC guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2873-2926.
2.
McCormick ML, Gavrila D, Weintraub NL: Role of oxidative stress in the pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2007;27:461-469.
3.
Lopez-Candales A, Holmes DR, Liao S, Scott MJ, Wickline SA, Thompson RW: Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am J Pathol 1997;150:993-1007.
4.
Theruvath TP, Jones JA, Ikonomidis JS: Matrix metalloproteinases and descending aortic aneurysms: parity, disparity, and switch. J Card Surg 2012;27:81-90.
5.
Owens GK, Kumar MS, Wamhoff BR: Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004;84:767-801.
6.
Ailawadi G, Moehle CW, Pei H, Walton SP, Yang Z, Kron I, Lau CL, Owens GK: Smooth muscle phenotypic modulation is an early event in aortic aneurysms. J Thorac Cardiovasc Surg 2009;138:1392-1399.
7.
Airhart N, Brownstein BH, Cobb JP, Schierding W, Arif B, Ennis TL, Thompson RW, Curci JA: Smooth muscle cells from abdominal aortic aneurysms are unique and can independently and synergistically degrade insoluble elastin. J Vasc Surg 2014;60:1033-1041.
8.
Liao S, Curci JA, Kelley BJ, Sicard GA, Thompson RW: Accelerated replicative senescence of medial smooth muscle cells derived from abdominal aortic aneurysms compared to the adjacent inferior mesenteric artery. J Surg Res 2000;92:85-95.
9.
Riches K, Angelini TG, Mudhar GS, Kaye J, Clark E, Bailey MA, Sohrabi S, Korossis S, Walker PG, Scott DJ, Porter KE: Exploring smooth muscle phenotype and function in a bioreactor model of abdominal aortic aneurysm. J Transl Med 2013;11:208.
10.
Mao N, Gu T, Shi E, Zhang G, Yu L, Wang C: Phenotypic switching of vascular smooth muscle cells in animal model of rat thoracic aortic aneurysm. Interact Cardiovasc Thorac Surg 2015;21:62-70.
11.
Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, Blanco-Colio L, Lavin B, Mallavia B, Tarin C, Mas S, Ortiz S, Egido J: Animal models of cardiovascular diseases. J Biomed Biotechnol 2011;2011:497841.
12.
Monk BA, George SJ: The effect of ageing on vascular smooth muscle cell behaviour - a mini-review. Gerontology 2015;61:416-426.
13.
Ragnauth CD, Warren DT, Liu Y, McNair R, Tajsic T, Figg N, Schroff R, Skepper J, Shanahan CM: Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation 2010;121:2200-2210.
14.
Wang M, Takagi G, Asai K, Resuello RG, Natividad FF, Vatner DE, Vatner SF, Lakatta EG: Aging increases aortic MMP-2 activity and angiotensin II in nonhuman primates. Hypertension 2003;41:1308-1316.
15.
Michaud M, Balardy L, Moulis G, Gaudin C, Peyrot C, Vellas B, Cesari M, Nourhashemi F: Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc 2013;14:877-882.
16.
Coppe JP, Desprez PY, Krtolica A, Campisi J: The senescence-associated secretory phenotype: the dark side of tumor suppression. Ann Rev Pathol 2010;5:99-118.
17.
Porter KE, Naik J, Turner NA, Dickinson T, Thompson MM, London NJ: Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg 2002;36:150-157.
18.
Turner NA, Aley PK, Hall KT, Warburton P, Galloway S, Midgley L, O'Regan DJ, Wood IC, Ball SG, Porter KE: Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. J Mol Cell Cardiol 2007;43:168-176.
19.
Turner NA, Mughal RS, Warburton P, O'Regan DJ, Ball SG, Porter KE: Mechanism of TNFalpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. Cardiovasc Res 2007;76:81-90.
20.
Riches K, Alshanwani AR, Warburton P, O'Regan DJ, Ball SG, Wood IC, Turner NA, Porter KE: Elevated expression levels of miR-143/5 in saphenous vein smooth muscle cells from patients with type 2 diabetes drive persistent changes in phenotype and function. J Mol Cell Cardiol 2014;74:240-250.
21.
Riches K, Warburton P, O'Regan DJ, Turner NA, Porter KE: Type 2 diabetes impairs venous, but not arterial smooth muscle cell function: possible role of differential RhoA activity. Cardiovasc Revasc Med 2014;15:141-148.
22.
Madi HA, Riches K, Warburton P, O'Regan DJ, Turner NA, Porter KE: Inherent differences in morphology, proliferation, and migration in saphenous vein smooth muscle cells cultured from nondiabetic and type 2 diabetic patients. Am J Physiol Cell Physiol 2009;297:C1307-C1317.
23.
Nilsson PM: Early vascular aging (EVA): consequences and prevention. Vasc Health Risk Manag 2008;4:547-552.
24.
Wilson WR, Herbert KE, Mistry Y, Stevens SE, Patel HR, Hastings RA, Thompson MM, Williams B: Blood leucocyte telomere DNA content predicts vascular telomere DNA content in humans with and without vascular disease. Eur Heart J 2008;29:2689-2694.
25.
Nelson G, Wordsworth J, Wang C, Jurk D, Lawless C, Martin-Ruiz C, von Zglinicki T: A senescent cell bystander effect: senescence-induced senescence. Aging Cell 2012;11:345-349.
26.
Cafueri G, Parodi F, Pistorio A, Bertolotto M, Ventura F, Gambini C, Bianco P, Dallegri F, Pistoia V, Pezzolo A, Palombo D: Endothelial and smooth muscle cells from abdominal aortic aneurysm have increased oxidative stress and telomere attrition. PLoS One 2012;7: e35312.
27.
Thompson AM, Wagner R, Rzucidlo EM: Age-related loss of SirT1 expression results in dysregulated human vascular smooth muscle cell function. Am J Physiol Heart Circ Physiol 2014;307:H533-H541.
28.
Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA: hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001;107:149-159.
29.
Badger SA, Jones C, McClements J, Lau LL, Young IS, Patterson CC: Surveillance strategies according to the rate of growth of small abdominal aortic aneurysms. Vasc Med 2011;16:415-421.
30.
Pei H, Tian C, Sun X, Qian X, Liu P, Liu W, Chang Q: Overexpression of microRNA-145 promotes ascending aortic aneurysm media remodeling through TGF-beta1. Eur J Vasc Endovasc Surg 2015;49:52-59.
31.
Booth GL, Kapral MK, Fung K, Tu JV: Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006;368:29-36.
32.
Medema RH, Macurek L: Checkpoint recovery in cells: how a molecular understanding can help in the fight against cancer. F1000 Biol Rep 2011;3:10.
33.
Holt DJ, Grainger DW: Multinucleated giant cells from fibroblast cultures. Biomaterials 2011;32:3977-3987.
34.
Shamanna RA, Hoque M, Lewis-Antes A, Azzam EI, Lagunoff D, Pe'ery T, Mathews MB: The NF90/NF45 complex participates in DNA break repair via nonhomologous end joining. Mol Cell Biol 2011;31:4832-4843.
35.
Constantinescu D, Csoka AB, Navara CS, Schatten GP: Defective DSB repair correlates with abnormal nuclear morphology and is improved with FTI treatment in Hutchinson-Gilford progeria syndrome fibroblasts. Exp Cell Res 2010;316:2747-2759.
36.
Kinner A, Wu W, Staudt C, Iliakis G: Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 2008;36:5678-5694.
37.
Wan G, Mathur R, Hu X, Zhang X, Lu X: miRNA response to DNA damage. Trends Biochem Sci 2011;36:478-484.
38.
Fiedler J, Stohr A, Gupta SK, Hartmann D, Holzmann A, Just A, Hansen A, Hilfiker-Kleiner D, Eschenhagen T, Thum T: Functional microRNA library screening identifies the hypoxamir miR-24 as a potent regulator of smooth muscle cell proliferation and vascularization. Antiox Redox Sig 2014;21:1167-1176.
39.
Badi I, Burba I, Ruggeri C, Zeni F, Bertolotti M, Scopece A, Pompilio G, Raucci A: MicroRNA-34a induces vascular smooth muscle cells senescence by SIRT1 downregulation and promotes the expression of age-associated pro-inflammatory secretory factors. J Gerontol A Biol Sci Med Sci 2015;70:1304-1311.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.